Metformin for Abdominal Aortic Aneurysm Growth Inhibition

• Status: Enrolling by invitation
• Trial end date: 2026-01-01
• Target enrollment: 0
• Participant gender: All

Summary

A multi-centre population-based open-label randomized controlled trial with allocation concealment and blinded outcome assessment will examine if up to 2g metformin daily slows AAA growth in patients with small AAAs who do not have diabetes.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Uppsala University Hospital
• Treatments: Metformin

Criteria

Inclusion Criteria:

1. Provision of written informed consent.

2. Male and female patients.

3. Age 50-80 years.

4. Documented AAA Ø 30-49 mm for men and 30-44 mm for women.

5. Fasting p-glucose <7.0 mmol/L. Fasting is defined as no caloric intake for ≥8 h.

Exclusion Criteria:

1. Short expected survival.

2. History of current or previous diabetes mellitus.

3. Current or previous use of metformin.

4. Not expected to tolerate metformin.

5. Contraindications to metformin treatment according to SmPC

6. Known or suspected connective tissue disorder (Marfans syndrome, etc), infected or inflammatory aneurysm, aneurysm development after aortic dissection or previous surgery of the infrarenal aorta.

7. Enrollment in either another investigational drug or medical device study or another investigational study of an approved drug or medical device within 30 days prior to enrollment of the current study.

8. If, in the opinion of the investigator, it is not in the patient's medical interest to participate in the study or the patient is unlikely to be able to comply with the study protocol.

9. Pregnancy.